SPECIALTY QUANTITY LIMIT PROGRAM

NEULASTA (pegfilgrastim) FULPHILA (pegfilgrastim-jmdp) UDENYCA (pegfilgrastim-cbqv) ZIEXTENZO (pegfilgrastim-bmez)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-Recommended dosing
Neulasta/Fulphila/Udenyca/ Ziextenzo (pegfilgrastim) injection 6 mg per 0.6 mL solution	2 per 28 days	 Patients with cancer receiving myelosuppressive chemotherapy: 6 mg subcutaneously once per chemotherapy cycle Pediatric patients: Based on body weight not to exceed adult doses Patients with hematopoietic subsyndrome of Acute Radiation Syndrome: 2 doses, 6mg each, subcutaneously one week apart.

III. REFERENCES

- 1. Neulasta [package insert]. Thousand Oaks, CA: Amgen Inc.; April 2019.
- 2. Fulphila [package insert]. Zurich, Switzerland: Mylan; May 2019.
- 3. Udenyca [package insert]. Redwood City, California: Coherus BioSciences, Inc: September 2019.
- 4. Ziextenzo [package insert]. Princeton, NJ: Sandoz Inc.; November 2019.

Specialty Quantity Limit Neulasta and pegfilgrastim biosimilars 1759-H P2019a.docx

© 2020 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

